ClinicalTrials.gg

Program

tusamitamab sonditecan

In Pfizer’s pipeline, CEACAM5-directed antibody-drug conjugate. Its studies are mostly in Colorectal Neoplasms, led by Pfizer.

Furthest: phase 1, since Nov 9, 20231 company-led study, 1 open or runningNext primary completion: Sep 12, 2029 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer11 open or runningphase 1since Nov 9, 2023Nov 9, 2023Sep 12, 2029phase 1 · NCT06131840
  • Named in Pfizer’s own pipeline as PF-08046050, phase 1, as of Nov 3, 2026 (source).
  • Named in sanofi’s own pipeline as SAR445953, phase 1, as of Sep 30, 2026 (source).

Also a collaborator on its studies: Sanofi.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 9, 2023First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT06131840 · 914 planned · United States, Canada, China and more

Ahead

  1. Sep 12, 2029Primary completion: phase 1 study in Colorectal NeoplasmsNCT06131840

TargetBeta

“CEACAM5-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“CEACAM5-Topo1 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of tusamitamab, a humanized, immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the tumor-associated antigen (TAA) carcinoembryonic antigen (CEA; carcinoembryonic antigen-related cell adhesion molecule 5; CEACAM5; CD66e) and conjugated t…”NCIt, read by Claude

Other programs on CEACAM5

ProgramCompanyFurthest phaseStudies
precemtabart tocentecanruleMerck KGaA, Darmstadt, Germanyphase 34
Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5Sino Biopharmaceuticalphase 22
Anti-CEACAM5 Antibody-drug Conjugate BMS-986490ruleBristol-Myers Squibbphase 21
Anti-CEACAM5 Antibody-drug Conjugate IBI3020ruleInnovent Biologicsphase 11
RO7821657ruleHoffmann-La Rochephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06131840Colorectal Neoplasms · United States, Canada, China and more1RecruitingSep 12, 2029914

How it is read

Names in the registry

  • “PF-08046050”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.